BioSpace News Archive

Cleveland Clinic cardiac surgery expertise is now accessible to eligible Eli Lilly and Company employees, retirees and their family members through the Cleveland Clinic Cardiac Concierge Program, in collaboration with Anthem Blue Cross and Blue Shield and its affiliated health plans.

Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced the initiation of patient dosing in its Phase 1 clinical trial to evaluate ANK-700 for the treatment of people with relapsing remitting multiple sclerosis (RRMS).

Akoya Biosciences, Inc., The Spatial Biology Company ® , today announced its support for the Human Cell Atlas (HCA) initiative, offering the CODEX ® solution’s single-cell, whole-tissue imaging capabilities to HCA members under favorable commercial terms.

CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has secured an extension to its Schedule I U.S. Drug Enforcement Agency (DEA) license that will allow the Company to conduct research on psychedelics-based pharmaceuticals

-- Adaptive Platform Trial is Evaluating Drugs and Investigational Products in the Treatment of Critically Ill COVID-19 Patients --

FDA-cleared Concussion Index is the only brain activity-based biomarker for rapid, objective baselining and assessment of concussion at injury and recovery time points

The state’s largest provider of pharmacy services to congregate care communities and group homes, Apothecare Pharmacy, LLC, has reached a vaccination milestone this week.

SiteOne Therapeutics Inc., a private biopharmaceutical company developing new treatments to address conditions involving hypersensitivity of the nervous system, today announced the appointment of John Mulcahy, Ph.D., as chief executive officer

New programs, designed in partnership with iDesign, will soon enable access to online courses from Michigan’s School of Social Work and Medical School, helping meet growing workforce demand in social work and learning health sciences

AbSci, a pioneering synthetic biology company that unifies biologic drug discovery and development processes, today announced a $125 million crossover financing.